COPENHAGEN, Denmark, July 16, 2026 /PRNewswire/ -- Novonesis, a global leader in biosolutions, today announced an agreement with TurtleTree, an innovator in precision fermented ingredients, and the first company to receive a US GRAS "No Objection Letter" for its precision fermented lactoferrin LF+®. Simultaneously, Novonesis is making a minor investment into TurtleTree. 321Catalyst Ventures, the CVC-arm of Mitsui Chemicals, Inc. (HQ: Tokyo) joins the investment. 
 Under the agreement, Novonesis will exclusively undertake efforts to scale, manufacture and commercialize LF+® for the earl…READ FULL ARTICLE